## Review setup
- **Input scope** Full manuscript text provided (Abstract, Introduction, five main sections, Conclusion, author contributions, declarations, acknowledgments). Figures and Tables are provided as captions and inline table text only; no high-resolution figure files, no supplementary materials, no reference list with full bibliographic entries.
- **Assessment boundary** Assessment is limited to the supplied text. Claims about figure content, table accuracy, and citation correctness are evaluated only to the extent that the supplied material permits. No external literature verification was performed.
- **Shared manuscript claim summary** The manuscript argues that Cas protein engineering has progressed through three tiers (directed evolution, structure-based rational design, integrated/multi-strategy protein engineering) following a "random exploration, precision modification, system integration" logic, and that AI and protein language models now act as cross-layer enabling tools plus an independent de novo design paradigm, together forming a closed-loop ecosystem that will yield miniaturized, broad-spectrum, high-precision editors for clinical and agricultural use.
- **Visible evidence base** Narrative synthesis of named variants and platforms (xCas9-3.7, SpG, SpRY, HiFiCas9, evoCas9, Sniper2L, SpCas9-Mut5, OpenCRISPR-1, FrCas9, HypaCas9, SuperFi-Cas9, HyperDriveCas9, MISER Cas9, mini-SaCas9, AsCas12f yham/hkra, AsCas12f1-M5, Al3Cas12f RKK, Cas12i.3, MIDAS, LbCas12a-RRV, ttLbCas12a Ultra, hfCas12Max, Flex-Cas12a Lbm6-RVQ); Table 1 and Table 2 on delivery; Table 3 on AI tools; Table 4 on strategy comparison; Fig. 1 to Fig. 4 as captions.
- **Missing materials affecting confidence** No reference list with titles/journals/years; no quantitative benchmarking tables with matched conditions; no figure files; no supplementary methods or search strategy; no statement of literature search date, database, or inclusion criteria; no data-availability or code-availability statement for the AI toolchain discussion.

## Reviewer
- **Overall assessment** This is a broad, well-organized narrative review that maps a genuinely useful conceptual structure onto a crowded field. The three-tier framing plus an AI cross-layer role is pedagogically clear and the AI tool table (Table 3) is a practical contribution. However, the manuscript is currently a taxonomy-and-assertion document rather than a critical synthesis. Several performance claims are stated as settled facts without matched quantitative context, the "fills a gap in systematic analysis" claim is not demonstrated against existing reviews, and the AI section mixes validated tools with speculative projections without consistently separating the two. The delivery tables (Table 1, Table 2) are largely disconnected from the protein-engineering argument that the title and abstract promise. The manuscript is readable and likely useful to newcomers, but the evidence base as supplied does not establish the stronger claims about superiority, mechanism, and clinical readiness.
- **Who would be interested in the results, and why** Protein engineers and genome-editing tool developers seeking an entry-level map of Cas optimization strategies; computational biologists and ML practitioners evaluating where protein language models and structure predictors fit into an editing-tool pipeline; translational researchers and process-development groups assessing miniaturized AAV-compatible editors; plant and agricultural biotechnology groups tracking species-adapted variants; reviewers and funding bodies needing a compact orientation to the field. The AI tool table and the strategy-comparison table are the elements most likely to be reused.
- **Major strengths**
  - The three-tier framework (directed evolution, rational design, integrated engineering) with AI as a cross-layer enabler is a coherent organizing device, and Table 4 makes the comparison operational rather than rhetorical.
  - Table 3 is a substantive, structured inventory of AI tools with architecture, advantages, limitations, applications, and references, which is more useful than a prose list.
  - The manuscript correctly and repeatedly states that AI-generated candidates require wet-lab validation and that AI does not replace traditional engineering, which is an appropriately calibrated position.
  - The bottleneck analysis in the AI section (data scarcity, non-standardized datasets, black-box interpretability, single-modal training, low wet-lab automation) is specific and actionable rather than generic.
  - Coverage of miniaturization routes (truncation of large Cas proteins versus native small Cas12f and TnpB/IscB) is a well-chosen axis that connects engineering to a concrete delivery constraint.
- **Major Concerns**

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Novelty and positioning
- **Claim pointer** The abstract states the study "fills a gap in systematic analysis within the field and provides a theoretical framework for tiered, synergistic modification."
- **Evidence pointer** Abstract; Introduction final paragraph; no comparison to prior reviews anywhere in the supplied text
- **Concern** The gap claim is asserted but never substantiated. The supplied material contains no discussion of existing reviews on Cas protein engineering, no statement of what prior syntheses covered, and no explicit delineation of what is new here beyond the three-tier labeling. The three-tier framing itself is a relabeling of a widely used distinction (random mutagenesis, structure-guided design, combined approaches), and the AI cross-layer role is presented as novel without evidence that it has not been articulated elsewhere.
- **Why it matters** For a review, the contribution is the synthesis, not the primary data. If the synthesis overlaps substantially with existing reviews, the manuscript's stated value proposition does not hold, and the reader cannot judge what to read here rather than elsewhere.
- **Resolution test** Provide an explicit comparison against at least three to five prior reviews in this space, stating for each what it covered and what the present manuscript adds. Either narrow the gap claim to a specific, defensible increment (for example, the AI tool taxonomy in Table 3, or the integration-layer decision logic) or remove the "fills a gap" language.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency for comparative performance claims
- **Claim pointer** Multiple variants are described as achieving superior performance, for example Sniper2L "eliminates single-base mismatch off-target events while maintaining wild-type editing efficiency," SpCas9-Mut5 "combines ultra-high specificity with lossless editing activity," and AsCas12f yham/hkra achieved "a tenfold increase in activity without increasing the risk of off-target effects."
- **Evidence pointer** Sections "Overcoming the activity-specificity trade-off," "A breakthrough expansion of PAM compatibility," "Miniaturized design"; no quantitative table or figure with matched assay conditions
- **Concern** These are strong, quantitative, comparative claims presented without the measurement context that determines whether they are meaningful. "Tenfold increase" is meaningless without specifying the assay, target site, cell type, dose, and comparator. "Lossless" and "eliminates" are absolute terms that require the detection limit of the assay to be stated. The manuscript provides no table of head-to-head benchmarks, no indication of whether numbers come from the original papers under their own conditions or from independent replication, and no discussion of the well-documented reproducibility issues in high-fidelity Cas9 variant comparisons.
- **Why it matters** A review that transmits uncontextualized performance numbers propagates exactly the comparability problem that hampers this field. Readers may adopt variants based on numbers that are not transferable across assays.
- **Resolution test** Add a benchmark table with columns for variant, parent scaffold, assay system, target site or library, dose, on-target metric, off-target metric, and source reference, with an explicit note where conditions are not comparable across rows. Soften absolute language ("eliminates," "lossless," "ultra-high") to match what the cited assays can detect, or state the detection limits.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Internal consistency between stated framework and presented content
- **Claim pointer** The abstract and title frame the review around Cas protein engineering for enhanced performance, and the Introduction states that the four bottlenecks (off-target, PAM, NHEJ outcomes, delivery) are "essentially closely associated with the intrinsic molecular properties of Cas proteins."
- **Evidence pointer** Introduction; Table 1; Table 2; Fig. 2
- **Concern** Table 1 and Table 2 plus Fig. 2 constitute a substantial delivery-method survey (pDNA, mRNA, RNP; AAV, AdV, LV, LNP, polymer, inorganic, DNA nanocages, electroporation, microinjection, exosomes) that is only weakly connected to protein engineering. Most entries are formulation and vector properties, not Cas protein properties. The manuscript does not explain why a protein-engineering review needs two full delivery tables, nor does it use them analytically, for example to derive the size ceiling that motivates miniaturization or the immunogenicity constraint that motivates specific surface modifications. The tables read as inserted reference material.
- **Why it matters** Unintegrated content dilutes the framework and inflates length without advancing the argument. It also creates an expectation of analysis that the text does not deliver.
- **Resolution test** Either integrate the delivery tables explicitly into the engineering argument (for example, derive the AAV packaging limit and use it to frame the miniaturization section, and connect RNP delivery to the stability and aggregation properties that protein engineering can tune), or move them to supplementary material and reduce the main text to the delivery constraints that directly drive protein design.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Attribution accuracy and mechanistic specificity
- **Claim pointer** Specific variants and mechanisms are attributed to specific teams and strategies, for example "Mark A. Behlke's team utilized a dual-screening system (positive and negative) in E. coli... to iteratively evolve a HiFiCas9 variant," "SuperFi-Cas9, developed by the University of Texas team," "The Doudna team's modifications to the Cas9 WED domain," and "The MIDAS modification method developed by the Chinese Academy of Sciences."
- **Evidence pointer** Sections "Overcoming the activity-specificity trade-off," "Enhancing specificity," "Enhanced efficiency," "Universal engineering and species-specific optimization"
- **Concern** Team attributions are used as evidence of provenance but are not verifiable from the supplied material, since no reference list with author affiliations is included. More substantively, several mechanistic descriptions are too compressed to be checkable. For example, the HiFiCas9 description does not name the specific mutations or explain how the positive/negative screen distinguishes on-target from off-target activity. The SuperFi-Cas9 description refers to "non-specific interactions at the DNA-binding interface and abnormal structural flexibility" without identifying residues or domains. The WED domain claim about "DNA unwinding efficiency" as "the central regulatory role" is stated as established without noting that this is one of several proposed determinants of Cas9 kinetics.
- **Why it matters** Mechanistic claims are the part of a review that specialists will scrutinize. Vague mechanism statements that read as settled can mislead non-specialist readers and will not survive expert review.
- **Resolution test** For each named variant, state the specific mutations or domains, the assay that established the mechanism, and the reference. Where a mechanism is contested or one of several models, say so explicitly. Remove or qualify team attributions that cannot be tied to a verifiable citation in the reference list.

- **Concern ID** R1-M5
- **Severity** Major
- **Blocking** No
- **Axis** Separation of validated results from projection
- **Claim pointer** The AI section presents a toolchain and then states that "AI-driven rational design effectively overcomes the coupling dilemma in traditional directed evolution... while cutting screening cycles and experimental costs by orders of magnitude," and that computational pipelines "support personalized therapeutic design... such as corrective edits for sickle cell anemia-causing HBB variants, accelerating clinical translation."
- **Evidence pointer** Section "Multidimensional advantages of AI-powered Cas protein engineering"; Section "Core bottlenecks and future perspectives"; Table 3
- **Concern** The section moves between demonstrated capabilities and aspirational projections without a consistent marker. "Orders of magnitude" cost and cycle reduction is a strong quantitative claim with no supporting measurement. The personalized HBB editing example is presented as an existing capability of computational pipelines, but the supplied text provides no evidence that an AI-designed editor has been used for a patient-specific HBB correction. Table 3 itself lists substantial limitations for nearly every tool (AlphaFold2/3 limitations in dynamic structures and complexes; ESMFold lower accuracy than AlphaFold; EVOLVEpro high computational demand and limited mutational space exploration; ProGen dependence on homology and poor generalization to orphan proteins), which sits in tension with the strong claims in the prose.
- **Why it matters** Overstating AI maturity in this field is a common failure mode and directly undermines the manuscript's otherwise well-calibrated caveats. It also risks misleading readers who are deciding whether to invest in these pipelines.
- **Resolution test** Mark each claim in this section as demonstrated, partially demonstrated, or projected, and cite the specific study for each demonstrated claim. Provide a source for the "orders of magnitude" figure or remove the quantification. Reframe the HBB example as an illustrative target class rather than an achieved AI-driven outcome, unless a specific study is cited.

- **Concern ID** R1-M6
- **Severity** Major
- **Blocking** No
- **Axis** Reproducibility of the review methodology
- **Claim pointer** The manuscript presents itself as a systematic analysis that "comprehensively map[s] the entire technical pathway for Cas protein improvement."
- **Evidence pointer** Abstract; Introduction; no methods section anywhere in the supplied text
- **Concern** There is no description of how the literature was identified, what databases and date range were used, what inclusion and exclusion criteria were applied, or how many studies were screened. "Comprehensively map the entire technical pathway" is a strong claim that requires either a systematic search or an explicit statement that the review is expert-narrative and selective. The current text does neither.
- **Why it matters** Readers cannot assess coverage bias. Notable omissions are difficult to detect without a stated search strategy, and the "entire technical pathway" claim invites the reader to assume completeness that a narrative review cannot guarantee.
- **Resolution test** Add a short methods paragraph stating search databases, date range, search terms, and selection criteria, or explicitly reframe the review as a selective expert synthesis and remove "entire" and "comprehensively" from the claims.

- **Minor Comments**

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Terminology consistency
- **Affected element** System classification in the Introduction
- **Evidence pointer** Introduction, paragraph 2
- **Issue** The text states the system "can be classified into Type I and Type II systems based on the number of Cas proteins, and is further subdivided into seven classes (Types I–VII)," then immediately describes Class I and Class II. The Type/Class terminology is used interchangeably and the initial "Type I and Type II" phrasing conflicts with the subsequent Class I/Class II framing.
- **Required correction** Standardize on Class 1 and Class 2 for the multi-subunit versus single-protein division, and reserve Type I to VII for the specific subtypes, consistent with the current accepted nomenclature.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Internal contradiction
- **Affected element** Rational design workflow description
- **Evidence pointer** Section "Structure-based rational design," paragraph 2
- **Issue** The paragraph states that rational design "does not require prior structural information of target proteins," which directly contradicts the preceding and following sentences establishing high-resolution structure as "the fundamental premise" and the core limitation of the approach.
- **Required correction** Delete or correct this sentence. The intended contrast is presumably with directed evolution, which does not require structural information.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Figure and table integration
- **Affected element** Fig. 1 through Fig. 4 and Tables 1 to 4
- **Evidence pointer** Inline captions throughout
- **Issue** Figures and tables are referenced but the surrounding text rarely interprets them. For example, Fig. 3 is cited once in a parenthetical and Table 3 is referenced only as "(Table 3)" at the end of a long paragraph. Table 4, which is the most analytically important table, is introduced with a single sentence.
- **Required correction** Add explicit interpretive sentences for each figure and table that state what the reader should conclude from it, and cross-reference Table 4 to the specific claims in the Conclusion.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Citation completeness
- **Affected element** Reference list
- **Evidence pointer** Not provided in the supplied material
- **Issue** The text cites over ninety references by number, including several that carry specific factual claims (for example the tenfold activity increase, the 34% to 80% efficiency improvement, the 3 to 4 fold genomic coverage increase). Without the reference list, none of these can be verified, and the manuscript cannot be assessed for citation accuracy.
- **Required correction** Ensure the reference list is complete and that each quantitative claim maps to a specific primary source rather than a review.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Precision of quantitative statements
- **Affected element** Applications and prospects section
- **Evidence pointer** Section "Applications and prospects," paragraph 1
- **Issue** The statement that engineered small Cas proteins "can achieve editing efficiencies of up to 90% in human cells without significant off-target effects or tissue toxicity" is presented without a specific variant, target, assay, or citation, and "without significant" is undefined.
- **Required correction** Attribute the figure to a specific variant and study, state the assay and target, and define the off-target and toxicity thresholds used.

- **Concern ID** R1-m6
- **Severity** Minor
- **Axis** Figure caption accuracy
- **Affected element** Fig. 1 caption, panel d
- **Evidence pointer** Fig. 1 caption
- **Issue** The caption states prime editing supports "small insertions (∼40 bp), small deletions (∼80 bp), and precise point mutations within approximately 30 bp flanking the Cas9 nicking site." These specific size limits are stated without a source and without noting that they are configuration-dependent and have been substantially extended in later PE variants.
- **Required correction** Cite the source for these limits and note that achievable insert size and edit window depend on the PE architecture and pegRNA design.

- **Concern ID** R1-m7
- **Severity** Minor
- **Axis** Redundancy
- **Affected element** Conclusion relative to main text
- **Evidence pointer** Conclusion, paragraphs 1 to 3
- **Issue** The Conclusion restates the three-tier framework and the AI cross-layer role at nearly the same level of detail as the Abstract and the final section of the main text, adding little synthesis.
- **Required correction** Condense the Conclusion and use the space for a decision-oriented summary, for example which strategy to choose under which structural-information and throughput constraints.

- **Technical failings that need to be addressed before the case is established** R1-M1 (gap claim unsubstantiated), R1-M2 (comparative performance claims lack matched quantitative context), R1-M4 (mechanistic and attribution claims not verifiable from supplied material), R1-M5 (validated results and projections not separated), R1-M6 (no search methodology for a review claiming comprehensive coverage). R1-M3 is a structural and integration issue that affects readability and focus rather than the core case.

- **Assessment against Nature-style criteria**
  - **Originality** Limited as presented. The three-tier framework is a reasonable pedagogical organization but is not a new conceptual contribution, and the AI cross-layer role is asserted rather than demonstrated to be novel. The AI tool table (Table 3) is the most original element, but its novelty is as a curated inventory rather than as an analytical advance. The gap claim in the abstract is not supported by any comparison to existing literature.
  - **Scientific importance** Moderate. The topic is important and the synthesis could be useful for orientation, particularly for groups entering the field or deciding where to place computational versus experimental effort. However, importance is currently carried by the topic rather than by the manuscript's analysis. The absence of matched benchmarking and of a critical treatment of conflicting results limits the value to specialists.
  - **Interdisciplinary readership** Potentially broad. The material spans protein engineering, structural biology, machine learning, delivery science, and translational and regulatory considerations, which is appropriate for a wide audience. The delivery tables and the AI tool table support this breadth. However, the weak integration of the delivery content and the uneven depth across sections mean the interdisciplinary appeal is more nominal than realized.
  - **Technical soundness** Insufficient as supplied. Quantitative claims lack measurement context, several mechanistic statements are too compressed to be checkable, one internal contradiction is present (R1-m2), and the reference list is not available for verification. The manuscript's own caveats about AI limitations are sound and well-judged, which makes the stronger claims elsewhere more conspicuous.
  - **Readability for nonspecialists** Good. The prose is clear, the tiered structure is easy to follow, and the tables are legible. Jargon is generally explained on first use. The main readability issue is length and repetition rather than clarity, and the unintegrated delivery tables interrupt the argument for a reader trying to follow the engineering narrative.

- **Recommendation posture** Currently not established from the provided evidence for the manuscript's stronger claims (gap-filling novelty, comparative performance superiority, AI-driven clinical readiness). The framework and the AI tool inventory are potentially publishable as a narrative review if the gap claim is narrowed or substantiated, quantitative claims are given matched context, validated results are separated from projections, and a search methodology or an explicit selectivity statement is added. Supportive of publication in a review-appropriate venue if these technical concerns are resolved; not supportable in its present form for a venue applying Nature-style originality and technical-soundness thresholds.

## Risk / unsupported claims
- **Unsupported (no evidence in supplied material):** The claim that the review "fills a gap in systematic analysis within the field." No comparison to prior reviews is provided.
- **Unsupported (no evidence in supplied material):** "Cutting screening cycles and experimental costs by orders of magnitude" attributed to AI-driven rational design. No measurement or source is given.
- **Unsupported (no evidence in supplied material):** The implication that computational pipelines currently enable personalized therapeutic design for HBB sickle cell variants. No study demonstrating an AI-designed editor applied to this target is cited in the supplied text.
- **Unsupported (no evidence in supplied material):** "Editing efficiencies of up to 90% in human cells without significant off-target effects or tissue toxicity" for engineered small Cas proteins. No variant, assay, or citation is specified.
- **Weak (stated as settled, context-dependent):** "Tenfold increase in activity without increasing the risk of off-target effects" for AsCas12f yham/hkra. Assay conditions and comparator are not stated.
- **Weak (stated as settled, context-dependent):** "Eliminates single-base mismatch off-target events" for Sniper2L and "lossless editing activity" for SpCas9-Mut5. Absolute terms require stated detection limits.
- **Weak (stated as settled, context-dependent):** The 34% to 80% editing efficiency improvement for Flex-Cas12a. Target, assay, and dose are not specified.
- **Weak (stated as settled, context-dependent):** The 3 to 4 fold genomic coverage increase for AsCas12f1-M5. The basis for coverage calculation is not given.
- **Weak (attribution not verifiable):** Team-level attributions (Behlke, Doudna, University of Texas, Chinese Academy of Sciences, Huida Genomics, Shanghai Jiao Tong University) cannot be verified because the reference list is not supplied.
- **Not assessable from supplied material:** Accuracy of Table 1, Table 2, Table 3, and Table 4 entries, since primary sources are not available for cross-checking.
- **Not assessable from supplied material:** Figure content and whether figures support the claims made in their captions, since figure files are not provided.
- **Not assessable from supplied material:** Coverage completeness of the literature, since no search strategy, database list, or date range is stated.